LadRx Corporation CYTR
Oct 5, 2022, 9:57 AM EDT
52-week range unavailable
- Market cap
- 11.77M
- Revenue (ttm)
- 250.00K
- Shares out
- 33.64M
- Forward P/E
- -1.17
- Volume
- 942
- Open
- 0.0922
- Previous close
- 0.09
- Day's range
- 0.09 – 0.0922
- Beta
- 2.28
- Price target
- 4.50 (+4900.0%)
- Earnings date
- Nov 11, 2022
Key statistics
- Enterprise value
- -5.59M
- PEG ratio
- 0.00
- Price / sales
- 47.09
- Price / book
- 0.62
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -6.83M
- Total cash
- 20.05M
- Total debt
- 0
- Return on equity
- -36.98%
- Short % of float
- 0.90%
- 50-day average
- 0.522941
- 200-day average
- 0.58
Analyst view
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 11, 2022
Expected Nov 11, 2022. Consensus EPS estimate -0.06.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2022 | Sep 1, 2022 | 0.00 | — | — | — |
| Aug 11, 2022 | Jun 1, 2022 | 0.00 | — | — | — |
| May 12, 2022 | Mar 1, 2022 | 0.00 | — | — | — |
| Nov 12, 2021 | Sep 1, 2021 | 0.00 | — | — | — |
| Aug 12, 2021 | Jun 1, 2021 | 0.00 | — | — | — |
About LadRx Corporation
CytRx Corporation, a biopharmaceutical company, engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company's lead candidates include linker activated drug release (LADR) -7, LADR-8, LADR-9, and LADR-10; and Aldoxorubicin, a conjugate of prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and to concentrate the drug at the site of the tumor. It also provides albumin companion diagnostic for cancer. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cytrx.com
News
Sorrento Therapeutics (OTCMKTS:SRNEQ) versus LadRx (OTCMKTS:CYTR) Financial Contrast 
Analyzing LadRx (OTCMKTS:CYTR) & SQZ Biotechnologies (NYSE:SQZ) 
Contrasting Sorrento Therapeutics (OTCMKTS:SRNEQ) and LadRx (OTCMKTS:CYTR) 
LadRx Corporation, Inc. to Present at the Virtual Life Science Investor Forum March 13th 
LadRx Planning NDA Submission under 505(b)(2) for Aldoxorubicin and Other Updates 
LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License 
Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts 
CytRx Highlights Orphazyme's Submission of European Marketing Authorisation for Arimoclomol to Treat Niemann-Pick Disease Type C 
Stocks That Hit 52-Week Lows On Monday 
Stocks That Hit 52-Week Lows On Friday
Your note
Sign in to keep a note on CYTR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| KRIEGSMAN STEVEN A | Chief Executive Officer | Stock Award(Grant) | Dec 14, 2017 | 387,597 |
| LEVITT DANIEL J | Officer | Stock Award(Grant) | Dec 31, 2013 | 157,706 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sabby Management, LLC | 2.90% | 974,945 | 643.37K | Mar 30, 2019 |
| Renaissance Technologies, LLC | 1.86% | 626,144 | 413.19K | Mar 30, 2019 |
| Vanguard Group, Inc. (The) | 0.91% | 304,476 | 200.92K | Mar 30, 2019 |
| Blackrock Inc. | 0.90% | 303,162 | 200.06K | Mar 30, 2019 |
| Geode Capital Management, LLC | 0.55% | 186,584 | 123.13K | Mar 30, 2019 |
| Deutsche Bank Aktiengesellschaft | 0.23% | 77,761 | 51.31K | Mar 30, 2019 |